Ian Chau

机构：Royal Marsden NHS Foundation Trust, Royal Marsden Hospital · ORCID：0000-0003-0286-8703

发表论文 859 篇 · 总被引 45935 次 · h-index 81

代表论文

• Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study (2025 · Journal of Clinical Oncology · 被引 48)
• Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors? (2025 · ESMO Open · 被引 21)
• 2094O SKYSCRAPER-07: A phase III, randomised study of atezolizumab (atezo) with or without tiragolumab (tira) in patients (pts) with unresectable esophageal squamous cell carcinoma (ESCC) that has not progressed following definitive concurrent chemoradiotherapy (dCRT) (2025 · Annals of Oncology · 被引 9)
• First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial (2025 · The Lancet Oncology · 被引 8)
• Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies (2025 · JCO Precision Oncology · 被引 6)
• The prognostic role of Claudin 18.2 in advanced gastric or gastroesophageal junction adenocarcinoma: a systematic literature review (2025 · ESMO Gastrointestinal Oncology · 被引 5)